Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Melanoma in 2017

Moving treatments earlier to move further forwards

Nature Reviews Clinical Oncology volume 15, pages 75–76 (2018)Cite this article

Subjects

In 2017, results from phase III trials demonstrated the impressive safety and efficacy of adjuvant targeted and immune therapies in patients with resectable stage III–IV melanoma, and raised questions about the surgical management of patients with microscopic sentinel-lymph-node metastases. For patients with unresectable disease, new overall survival data added to the debate about the relative benefits of single-agent anti-PD-1 versus combined anti-PD-1 and anti-CTLA-4 immunotherapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Luke, J. J. et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463–482 (2017).

    Article  CAS  PubMed  Google Scholar 

  2. Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).

    Article  CAS  PubMed  Google Scholar 

  3. Eggermont, A. M. et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N. Engl. J. Med. 375, 1845–1855 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).

    Article  CAS  PubMed  Google Scholar 

  5. Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).

    Article  CAS  PubMed  Google Scholar 

  6. Gershenwald, J. E. et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67, 472–492 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 376, 2211–2222 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Long, G. V. et al. Outcomes in patients (pts) treated with ipilimumab (ipi) after pembrolizumab (pembro) in KEYNOTE-006 [abstract]. Pigm. Cell Melanoma Res. 30, 76–156 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

M.A.D. acknowledges funding support from the US National Cancer Institute (grants 1R01CA187076-02, 1U54CA224070-01, and 2T32CA009666-21), The Cancer Prevention and Research Institute of Texas (RP160183), the Melanoma Research Alliance, and the Melanoma Research Foundation. Both M.A.D and K.T.F. acknowledge funding support from the Dr Miriam and Sheldon G. Adelson Medical Research Foundation.

Author information

Authors and Affiliations

  1. Michael A. Davies is at the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0430, Houston, Texas 77030, USA.,

    Michael A. Davies

  2. Keith T. Flaherty is at the Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA.,

    Keith T. Flaherty

Authors
  1. Michael A. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith T. Flaherty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith T. Flaherty.

Ethics declarations

Competing interests

M.A.D. has served on advisory boards for BMS, Novartis, Roche/Genentech, Sanofi-Aventis, and Vaccinex, and has been the Principal Investigator of studies funded by grants to his institution from AstraZeneca, BMS, Oncothyreon, Roche/Genentech, and Sanofi-Aventis. K.T.F. has served on advisory boards for BMS, Merck, Novartis, and Roche/Genentech, and has received grant support from Novartis.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davies, M., Flaherty, K. Moving treatments earlier to move further forwards. Nat Rev Clin Oncol 15, 75–76 (2018). https://doi.org/10.1038/nrclinonc.2017.183

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.183

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer